The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.

Slides:



Advertisements
Similar presentations
Optimal revascularization strategy in patients with three-vessel disease and/or left main disease The 2-year Outcomes of the SYNTAX Trial A. Pieter Kappetein,
Advertisements

Lésion du tronc commun : reste-t-il une place pour la chirurgie ? La vision de l’angioplasticien Y. Louvard, ICPS, Massy.
Is this the “spioenkop” for CABG?
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
ARTS I & II Keith D Dawkins Southampton University Hospital.
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
PCI VS CABG JOURNAL REVIEW
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Journal Club: Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease Tiffany Sun, MD May 19, 2009.
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Multi-vessel disease and intracoronay physiology Combat MI 2009 Kees-joost Botman MD, PhD Catharina hospital Eindhoven Heart Institute The Netherlands.
Stent or Surgery: What is Best for a Woman ? Dr R H Stables Cardiothoracic Centre Liverpool UK.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
Determination of the RAdial versus GrOiN coronary angioplasty The Result of DRAGON Trial Shigeru Saito, MD Department of Cardiology and Catheterization.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
USCV September of 25 The safety and effectiveness of the TAXUS Express2 Stent System have not been established in the following patient.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Lianglong Chen MD PhD FACC
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Multivessel Coronary Artery Disease
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Multivessel PCI in an Era of Freedom and FAME Michael J. Cowley, MD, FSCAI Nothing to Disclose.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Revascularization Strategy: Syntax Score and Beyond
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
On behalf of the PRECOMBAT Investigators
On behalf of all principal COMPARE II investigators:
Vladimir Ganyukov, MD, PhD
SYNTAX at 2 Years: This Interventionalist’s Perspective
On behalf of J. Belardi, M. Leon, L. Mauri,
The Guidelines Should Be Change!
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Cardiovacular Research Technologies
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
On behalf of all principal COMPARE II investigators:
FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Long Term Clinical Results from the Endeavor Program: 5-Year Follow up
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
Glenn N. Levine et al. JACC 2011;58:e44-e122
Presentation transcript:

The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries Friedrich W. Mohr MD PhD Patrick W. Serruys MD PhD On behalf of the SYNTAX investigators Conflicts of Interest: None

Background l In the past five years several studies that have compared contemporary treatment of CAD by CABG and PCI (e.g. New York Registry) have been reported. These trials showed a risk-adjusted decrease in 5-year mortality in favor of CABG when the proximal LAD was involved. Hannan et al, New Engl J Med 2008;335:

To demonstrate improvements in current stent therapy, the results of recent PCI studies were compared to previous randomized trials (e.g. ARTS II). These studies showed a clear improvement in PCI results but compared to historical CABG data. Background II Serruys et al, EuroIntervention 2008;3:

23 US Sites 62 EU Sites Total enrollment N=3075 Stratification: LM and Diabetes Two Registry Arms Randomized Arms N=1800 TAXUS * N=903PCIn=198 CABGn=1077 CABGN=897 No FU N=428 5yr FU N=649 + SYNTAX Trial Design PCIN=198 CABGN=1077 vs. * TAXUS Express

Registries Objective Patients were identified who were not candidates for randomization based on clinical or anatomical characteristics and formed the basis for the registry experience: Who were not candidates for CABG (inoperable patients) Who were not candidates for PCI (technically not feasible)

Registries Methodology Treatment schedule and follow up visits identical with RCT Major adverse cardiac and cerebrovascular events 100% monitored 20% of patient data at each site (every fifth patient) was fully monitored No statistical comparisons between randomized and registry were performed

12 mo Follow up N=191 (99.5%) Patient Disposition: PCI Registry Lost to Follow-up (N=1) Withdrew Consent 1 Medical Treatment 4 CABG 1 Per-Protocol N=192 (100%) ITT Enrolled N=198

ITT Enrolled N= mo Follow up N=633 (98.2%) Patient Disposition: CABG Registry Lost to Follow-up (N=10) Withdrew Consent (N=1) Randomly assigned to 5y Follow-up N=649 No Treatment 3 Medical Treatment 2 Per-Protocol N=644 (100%)

Reasons for Registry Allocation PCI Registry- CABG ineligible due to: Co-morbidities (70.7%) No graft material (9.1%) Small or poor quality of distal vessel (1.5%) Patient refused CABG (5.6%) Other (13.1%) CABG Registry- PCI ineligible due to: Complex anatomy (70.9%) Untreatable CTO (22.0%) Unable to take anti-platelet medications (0.9%) Patient refused PCI (0.5%) Other (5.7%)

Patient Characteristics Notable Differences PCI RCT + Registry TAXUS RCT n=903 PCI Reg n=192 Age, mean±SD (y)65.2 ± ± 10 Male, % SYNTAX score28.4 ± ± 12.3 Diabetes, % Hyperlipidemia, % Current smoker, % Prior MI, % Unstable angina, % Add. EuroSCORE, mean±SD3.8 ± ± 3.1 Total Parsonnet score, mean±SD 8.5 ± ± 9.5 * For descriptive purposes only; no statistical comparisons done

Procedural Characteristics Notable Differences: PCI RCT + Registry TAXUS RCT * n=903 PCI Reg n=192 Staged Procedure, % Bi/trifurcation lesions treated, % Lesions treated, mean±SD3.6 ± ± 1.3 Stents implanted, mean±SD4.6 ± ± 1.8 Total length implanted, mm86.1 ± ± 41.2 Range, mm Long stenting (>100 mm), % * For descriptive purposes only; no statistical comparisons done

CABG RCT N=897 CABG Reg N=644 Age, mean±SD (y)65.0 ± ± 9.4 Male, % SYNTAX score, mean±SD29.1 ± ± 13.3 Diabetes, % Hypertension, % Hyperlipidemia, % Current smoker, % Prior MI, % Unstable angina, % Add. EuroSCORE, mean±SD3.8 ± ± 2.7 Total Parsonnet score, mean±SD 8.4 ± ± 7.1 Patient Characteristics Notable Differences CABG RCT + Registry * For descriptive purposes only; no statistical comparisons done

Procedural Characteristics Notable Differences CABG RCT + Registry Procedure-related CABG RCT * n=897 CABG Reg n=644 Off-pump surgery, % Graft revascularization, % At least one arterial graft Arterial graft to LAD LIMA + venous Double LIMA/RIMA Complete arterial revascularization Venous graft only Grafts per patient, mean ±SD2.8 ± ± 0.9 Distal anastomoses, mean ±SD3.2 ± ± 1.0 * For descriptive purposes only; no statistical comparisons done

12 Month MACCE Rates PCI Registry (N=192) Patients (%) Per-protocol population All Death CVA MI Death/CVA/MI Revascularization Total MACCE 25 In-Hospital MACCE

Event Rates to 12 Months: PCI Registry 012 Cumulative Event Rate (%) % All-Cause Death % CVA 0 12 Cumulative Event Rate (%) % 0 Months Since Allocation % 0 MI 012 Cumulative Event Rate (%) Months Since Allocation % Revascularization Cumulative Event Rate (%)

012 Cumulative Event Rate (%) Event Rate ± 1.5 SE Months Since Allocation 6 Per-protocol population Overall MACCE to 12 Months PCI Registry 20.4%

DeathRevascMIMACCEStroke Patients (%) 30 Day MACCE Post-Procedure CABG Registry (N=644)

12 Month MACCE Rates CABG Registry (N=644) Per-protocol population All Death CVA MI Death/CVA/MI Revascularization Total MACCE 8.8 In-Hospital MACCE Patients (%)

Event Rates to 12 Months: CABG Registry 012 Cumulative Event Rate (%) % All-Cause Death 012 Cumulative Event Rate (%) % CVA 012 Cumulative Event Rate (%) Months Since Allocation 6 2.5% MI 012 Cumulative Event Rate (%) Months Since Allocation 6 3.0%Revascularization

012 Cumulative Event Rate (%) Event Rate ± 1.5 SE Months Since Allocation 6 Per-protocol population Overall MACCE to 12 Months CABG Registry 8.8%

Conclusions Registries Patients (N=1275) were identified as unsuitable candidates for randomization based on clinical or anatomical characteristics, and formed the basis for the registry experience Patients (N=198) who were not candidates for CABG form a small population to study the outcomes of inoperable patients Patients (N=1077) who were not candidates for PCI form an ideal population to study the results of current surgical practice

PCI registry patients have the highest co-morbidity as expressed by highest EuroSCORE & Parsonnet scores In this surgically inoperable PCI registry the 12 month outcomes are: All Cause Death 7.3% CVA 0.0% MI 4.2% Repeat Revascularization 12.0% MACCE 20.4% Conclusions PCI Registry

The CABG registry patients who are technically unsuitable for PCI have the most complex lesion anatomy as expressed by a higher SYNTAX score In the CABG registry the 12 month outcomes are: All Cause Death 2.5% CVA 2.2% MI 2.5% Repeat Revascularization 3.0% MACCE 8.8% Conclusions CABG Registry

General Conclusions SYNTAX Trial The SYNTAX trial has enrolled a large number of patients with LM and/or 3 VD to evaluate optimal strategies of care. In these patients we can conclude: The Primary Endpoint (12 months MACCE) in this non- inferiority trial for PCI was not met. PCI continues to improve as do surgical techniques In this trial the Heart Team concluded that CABG remains the only treatment option for at least 1/3 of the patients screened In patients who are not candidates for PCI, surgical results are excellent In patients who are not candidates for CABG, PCI is a viable option